RU2478100C2 - Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы - Google Patents

Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы Download PDF

Info

Publication number
RU2478100C2
RU2478100C2 RU2010116759/04A RU2010116759A RU2478100C2 RU 2478100 C2 RU2478100 C2 RU 2478100C2 RU 2010116759/04 A RU2010116759/04 A RU 2010116759/04A RU 2010116759 A RU2010116759 A RU 2010116759A RU 2478100 C2 RU2478100 C2 RU 2478100C2
Authority
RU
Russia
Prior art keywords
cyclopentyl
pyrimido
oxo
ylamino
methyl
Prior art date
Application number
RU2010116759/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116759A (ru
Inventor
Джонатан Джеймс ХОЛЛИК
Стюарт Дональд ДЖОУНС
Клер Джун ФЛИНН
Майкл Джордж ТОМАС
Original Assignee
Сайкласел Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719038A external-priority patent/GB0719038D0/en
Priority claimed from GB0806844A external-priority patent/GB0806844D0/en
Application filed by Сайкласел Лимитед filed Critical Сайкласел Лимитед
Publication of RU2010116759A publication Critical patent/RU2010116759A/ru
Application granted granted Critical
Publication of RU2478100C2 publication Critical patent/RU2478100C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2010116759/04A 2007-09-28 2008-09-29 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы RU2478100C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0719038.2 2007-09-28
GB0719038A GB0719038D0 (en) 2007-09-28 2007-09-28 Compound
GB0806844.7 2008-04-15
GB0806844A GB0806844D0 (en) 2008-04-15 2008-04-15 Compound
PCT/GB2008/003305 WO2009040556A1 (en) 2007-09-28 2008-09-29 Pyrimidine derivatives as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013108456A Division RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Publications (2)

Publication Number Publication Date
RU2010116759A RU2010116759A (ru) 2011-11-10
RU2478100C2 true RU2478100C2 (ru) 2013-03-27

Family

ID=40199600

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010116759/04A RU2478100C2 (ru) 2007-09-28 2008-09-29 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
RU2013108456A RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013108456A RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Country Status (9)

Country Link
US (3) US8563542B2 (index.php)
EP (2) EP2610256B1 (index.php)
JP (2) JP5410432B2 (index.php)
CN (1) CN101878216B (index.php)
CA (1) CA2700979C (index.php)
ES (2) ES2585110T3 (index.php)
PL (2) PL2610256T3 (index.php)
RU (2) RU2478100C2 (index.php)
WO (1) WO2009040556A1 (index.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748696C2 (ru) * 2016-03-04 2021-05-28 Аньхой Нью Стар Фармасьютикал Дивелопмент Ко., Лтд Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
JP5380447B2 (ja) 2007-08-15 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体
BRPI0817315A2 (pt) 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
JP5410432B2 (ja) * 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
CN102076691A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
WO2010008454A1 (en) 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
UY32717A (es) 2009-06-17 2011-01-31 Vertex Pharma Inhibidores de la replicación de virus de la gripe
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
MX2012003484A (es) 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
SG189043A1 (en) 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2012083117A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP3738964A1 (en) * 2013-03-15 2020-11-18 Dana Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
AU2014348752C1 (en) 2013-11-13 2019-11-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
SG10201804026WA (en) 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
KR101517414B1 (ko) * 2014-04-24 2015-05-04 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
PT3233882T (pt) 2014-12-16 2020-01-21 Kayla Therapeutics Dinucleótidos cíclicos fluorados para a indução de citocinas
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
CN112166113A (zh) 2017-11-02 2021-01-01 卡里科生命科学有限责任公司 整合应激通路的调节剂
IL274406B2 (en) * 2017-11-02 2024-04-01 Calico Life Sciences Llc Modulators of the integrated stress pathway
ES3047933T3 (en) 2019-08-16 2025-12-05 Cyclacel Pharmaceuticals Inc Process for the preparation of a pyrimidino-diazepine derivative
WO2021032959A1 (en) * 2019-08-16 2021-02-25 Cyclacel Limited Crystalline forms of pyrimidino diazepine derivative
EP4034132B1 (en) 2019-09-27 2026-02-25 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
IL316085A (en) 2022-04-08 2024-12-01 Inhibrx Biosciences Inc Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100194A1 (en) * 2004-10-04 2006-05-11 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007095188A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
EA008778B1 (ru) * 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117635D0 (en) 1991-08-15 1991-10-02 British Telecomm Phase shifter
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005117944A2 (en) 2004-05-26 2005-12-15 The Texas A & M University System Hsp20 inhibits amyloidogenesis and neurotoxicity
ES2339480T3 (es) 2005-06-24 2010-05-20 Eli Lilly And Company Derivados de tetrahidrocarbazol utiles como moduladores del receptor de androgenos (sarm).
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
SI2139892T1 (sl) * 2007-03-22 2011-12-30 Takede Pharmaceutical Company Ltd Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
JP5410432B2 (ja) 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008778B1 (ru) * 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
US20060100194A1 (en) * 2004-10-04 2006-05-11 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007095188A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748696C2 (ru) * 2016-03-04 2021-05-28 Аньхой Нью Стар Фармасьютикал Дивелопмент Ко., Лтд Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение

Also Published As

Publication number Publication date
EP2205603A1 (en) 2010-07-14
US9493471B2 (en) 2016-11-15
EP2205603B1 (en) 2014-01-15
EP2610256A1 (en) 2013-07-03
US20140066436A1 (en) 2014-03-06
RU2010116759A (ru) 2011-11-10
RU2623221C2 (ru) 2017-06-23
JP5863196B2 (ja) 2016-02-16
PL2610256T3 (pl) 2016-11-30
JP2010540509A (ja) 2010-12-24
PL2205603T3 (pl) 2014-07-31
CA2700979C (en) 2017-06-20
ES2457394T3 (es) 2014-04-25
HK1187895A1 (en) 2014-04-17
CN101878216A (zh) 2010-11-03
HK1146042A1 (en) 2011-05-13
RU2013108456A (ru) 2014-09-10
EP2610256B1 (en) 2016-04-27
CN101878216B (zh) 2013-07-10
JP5410432B2 (ja) 2014-02-05
US20150344486A1 (en) 2015-12-03
US8563542B2 (en) 2013-10-22
US9133199B2 (en) 2015-09-15
WO2009040556A1 (en) 2009-04-02
US20110046093A1 (en) 2011-02-24
JP2014076994A (ja) 2014-05-01
ES2585110T3 (es) 2016-10-03
CA2700979A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
RU2478100C2 (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
AU2011217961B2 (en) Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
JP3876254B2 (ja) 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
US8592581B2 (en) Trisubstituted purine derivatives
EP1786779B1 (en) 4-arylazo-3,5-diamino-pyrazole compounds and use thereof
US9233965B2 (en) 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta
JP2007504159A (ja) プロテインキナーゼ阻害剤としての化合物および組成物
EP1589967B1 (en) Benzthiazole-3 oxides useful for the treatment of proliferative disorders
JP2005519087A (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
US20110118269A1 (en) Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
US20230312576A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
HK1146042B (en) Pyrimidine derivatives as protein kinase inhibitors
HK1187895B (en) Pyrimidine derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PD4A Correction of name of patent owner